Clinical trials: Endocrine System Disorder
Diabetes Mellitus, Type 1
Participant-Reported Outcomes With the Accu-Chek® Solo Micropump System
This interventional device study aims to compare mainly standard Multiple Daily Injection (MDI) therapy vs. Accu-Chek® Solo Micropump System and investigates participant satisfaction.
- Trial name
- PRO Solo (NCT03478969)
- Testing
- Accu-Chek® Solo micropump system, mylife™ OmniPod® Insulin Management System, Multiple Daily Injections (MDI) therapy
- Where
- 21 sites in Austria, Germany and 2 more
- Volunteers
- 181 people
- Sponsor
- Hoffmann-La Roche
Wounds, Wound of Skin
A Clinical Investigation to Follow the Progress of Exuding Chronic Wounds Using Mepilex® Up as the Primary Dressing.
The goal of this clinical trial is to follow the progress of wounds in those with venous leg ulcers and diabetic foot ulcers while using an absorbent dressing called Mepilex Up.
- Conditions
- Wounds, Wound of Skin, Wound Leg, Wound; Foot
- Trial name
- NCT05588583
- Testing
- Mepilex Up
- Where
- 4 sites in United States
- Volunteers
- 68 people
- Sponsor
- Molnlycke Health Care AB
Diabetes Mellitus, Type 2
Study to Evaluate Safety and Efficacy of Dapagliflozin and Saxagliptin in Patients With Type 2 Diabetes Mellitus (T2DM) Aged 10 to Below 18 Years Old
The primary objective of this study is to determine if there will be a greater mean reduction from baseline in glycated hemoglobin (HbA1c) achieved after 26 weeks of oral double-blind add-on therapy of dapagliflozin or…
- Trial name
- NCT03199053
- Testing
- Dapagliflozin, Saxagliptin
- Where
- 122 sites in United States, Argentina and 21 more
- Volunteers
- 256 people
- Sponsor
- AstraZeneca
Secondary Hyperparathyroidism (SHPT) in Subjects With Chronic Kidney Disease (CKD) on Hemodialysis
MT1013 Injection for the Treatment of Secondary Hyperparathyroidism in Patients With Chronic Kidney Disease
This is a randomized, positive controlled, and placebo-controlled phase II clinical study to evaluate the efficacy and safety of MT1013 injection in the treatment of chronic kidney disease with secondary hyperparathyroidism…
- Trial name
- NCT06690242
- Testing
- MT1013, Etelcalcetide Hydrochloride
- Where
- China
- Volunteers
- 115 people
- Sponsor
- Shaanxi Micot Pharmaceutical Technology Co., Ltd.
Diabetes Mellitus, Type 2
A Clinical Trial of MK-1403 in Participants With Type 2 Diabetes Mellitus (MK-1403-006)
The purpose of this study is to learn about the safety and if people tolerate a study medicine called MK-1403. The study will also measure what happens to MK-1403 in the body of a person with type 2 diabetes (T2D) over time…
- Trial name
- NCT07242469
- Testing
- MK-1403 + additive coformulation
- Where
- 5 sites in United States
- Volunteers
- 53 people
- Sponsor
- Merck Sharp & Dohme LLC
Hypogonadotropic Hypogonadism
Safety and Efficacy of BGS649 in Male Obese Subjects With Hypogonadotropic Hypogonadism
The purpose of this study is to evaluate the safety and efficacy of BGS649 in male obese subjects with hypogonadotropic hypogonadism. All subjects will be treated for a maximum of 24 weeks.
- Trial name
- NCT02730169
- Testing
- BGS649
- Where
- 63 sites in United States, Italy and 2 more
- Volunteers
- 271 people
- Sponsor
- Mereo BioPharma
Diabetes Mellitus, Type 2
Efficacy, Safety, and Tolerability of Once Daily Oral Administration of AZD5004 Versus Placebo for 26 Weeks in Adults With Type 2 Diabetes Mellitus.
This is a Phase IIb, randomised, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy, safety and tolerability of AZD5004 in adults with type 2 diabetes mellitus, compared to placebo and active…
- Trial name
- SOLSTICE (NCT06579105)
- Testing
- AZD5004, Semaglutide
- Where
- 97 sites in United States, Canada and 7 more
- Volunteers
- 406 people
- Sponsor
- AstraZeneca
Ovarian Epithelial Cancer, Fallopian Tube Cancer
p53 Gene in Treatment of Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer
The study objective is to investigate the efficacy and safety of p53 combined with chemotherapy (cisplatin and paclitaxel) in treatment of recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer.
- Conditions
- Ovarian Epithelial Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Trial name
- NCT02435186
- Testing
- p53 gene, Cisplatin, Paclitaxel
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Shenzhen SiBiono GeneTech Co.,Ltd
Metastatic Pancreatic Ductal Adenocarcinoma
A Study of the Safety and Tolerance of CAN04 in Combination With FOLFIRINOX in Subjects With Metastatic Pancreatic Ductal Adenocarcinoma
This study will consider the safety and effectiveness of a study drug, CAN04, in combination with FOLFIRINOX, in the treatment of metastatic pancreatic ductal adenocarcinoma.
- Trial name
- CAPAFOUR (NCT04990037)
- Testing
- CAN04, FOLFIRINOX
- Where
- 9 sites in France, Spain
- Volunteers
- 25 people
- Sponsor
- Cantargia AB
Diabetes Mellitus, Type 2
A Study of LY900014 in Participants With Type 2 Diabetes on Insulin Injection Therapy
The study will be conducted in participants with type 2 diabetes on insulin injection therapy to investigate how the body processes LY900014 and the effect of LY900014 on blood sugar levels.
- Trial name
- NCT02703337
- Testing
- LY900014, Insulin Lispro
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- Eli Lilly and Company
Thyroid Cancer
Efficacy and Tolerability of ZD6474 in Patients With Thyroid Cancer
The purpose of this open label, two stage, phase II study is to evaluate the efficacy and tolerability of ZD6474 in patients with locally advanced or metastatic hereditary medullary thyroid carcinoma.
- Trial name
- NCT00098345
- Testing
- ZD6474 (vandetanib)
- Where
- 6 sites in United States, France
- Volunteers
- 40 people
- Sponsor
- Genzyme, a Sanofi Company
Type 2 Diabetes
Bioequivalence Study of Metformin Hydrochloride Extended Release 750 mg Tablets Versus Glucophage XR® 750 mg Tablet in Healthy Volunteers Under Fed Conditions.
Objective: To study Bioequivalence of Metformin Hydrochloride Extended Release 750 mg Tablets (Test formulation, Torrent Pharmaceuticals Ltd., India) Versus Glucophage XR® 750 mg Tablet (Reference formulation, Bristol-Myers…
- Trial name
- NCT01089205
- Testing
- Metformin
- Sponsor
- Torrent Pharmaceuticals Limited
Diabetes Mellitus, Type 2
Pioglitazone Add-on Study in Patients With Type 2 Diabetes Mellitus
The purpose of this study is to determine the safety and efficacy of an investigational drug in patients with type 2 diabetes mellitus.
- Trial name
- NCT00086502
- Testing
- Comparator: Sitagliptin, Comparator: Pioglitazone, Metformin
- Volunteers
- 353 people
- Sponsor
- Merck Sharp & Dohme LLC
Neoplasms, Non-small-cell Lung Cancer
A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines.
The purpose of this study is to learn about the: safety (the effect of the study medicine on the participant's body), effects of the study medicine alone or in combination with sasanlimab - the best amount of the study medicine.
- Conditions
- Neoplasms, Non-small-cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Renal Cell Carcinoma
- Trial name
- NCT06546553
- Testing
- PF-07826390, sasanlimab, SOC (anti-PD-1 + platinum -based chemo)
- Where
- 8 sites in United States
- Volunteers
- 10 people
- Sponsor
- Pfizer
Type 2 Diabetes
Pivotal Trial of a Digital Therapeutic for the Treatment of Type 2 Diabetes
BT-001 is a software program intended to help patients with type 2 diabetes, under the guidance of their physician, improve glycemic control (i.e., levels of blood sugar).
- Trial name
- NCT04886388
- Testing
- BT-001, Physician-guided Standard of Care for type 2 diabetes
- Where
- 6 sites in United States
- Volunteers
- 668 people
- Sponsor
- Better Therapeutics
Type 1 Diabetes, Type 1 Diabetes (Juvenile Onset)
R-5280 in Newly Diagnosed Patients With Type 1 Diabetes
Evaluating the adverse events and tolerance of R-5280 in Mitigating Type 1 Diabetes in Newly Diagnosed Patients
- Conditions
- Type 1 Diabetes, Type 1 Diabetes (Juvenile Onset), Diabetes Mellitus, Type 1
- Trial name
- R-5280 (NCT06057454)
- Testing
- R-5280
- Where
- 3 sites in United States
- Volunteers
- 9 people
- Sponsor
- Rise Therapeutics LLC
Acromegaly
Pegvisomant And Sandostatin LAR Combination Study
The purpose of this study is to compare the safety and tolerability of combination therapy with Sandostatin LAR plus Pegvisomant to that of Sandostatin LAR alone or Pegvisomant alone.
- Trial name
- NCT00068029
- Testing
- Pegvisomant/ Sandostatin LAR, Sandostatin LAR, Pegvisomant
- Where
- 33 sites in United States, Australia and 10 more
- Volunteers
- 75 people
- Sponsor
- Pfizer
Hypercortisolism, Diabetes Mellitus, Type 2
Study to Determine the Prevalence of Hypercortisolism in Patients With Type 2 Diabetes and Treatment With Korlym® (Mifepristone) (CATALYST)
This is a Phase 4 study with 2 parts: Part 1 (Prevalence Phase) is non-interventional and will assess the prevalence of hypercortisolism in a population with difficult to control type 2 diabetes (T2D) (hemoglobin A1c ≥7.5%)…
- Trial name
- NCT05772169
- Testing
- Mifepristone 300 MG [Korlym]
- Where
- 36 sites in United States
- Volunteers
- 1,113 people
- Sponsor
- Corcept Therapeutics
Diabetes, Diabetes Mellitus, Type 1
Observational Study of Patients With Diabetes Using Levemir® FlexPen®
This study is conducted in Asia. This study is a prospective, open, uncontrolled, observational surveillance study with Levemir® FlexPen® conducted in Korea.
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- NCT00670683
- Testing
- insulin detemir
- Where
- South Korea
- Volunteers
- 797 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
Safety and Efficacy of Linagliptin in Type-2-diabetes Mellitus Patients With Moderate to Severe Renal Impairment
The objective of the current study is to investigate the efficacy, safety and tolerability of linagliptin (5 mg / once daily) compared to placebo given over 12 weeks in drug naive or previously treated type 2 diabetic patients…
- Trial name
- NCT01087502
- Testing
- Glimepiride, Linagliptin
- Where
- 52 sites in United States, Australia and 7 more
- Volunteers
- 241 people
- Sponsor
- Boehringer Ingelheim
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.